Ratings by JPMorgan (Priyanka Grover)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/8/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
8.41 (8.56) |
1.78% | Details | |
| 7/8/2026 | Relay Therapeutics | RLAY | New Coverage | Overweight (N/A) |
18.90 (19.91) |
5.34% | Details | |
| 4/30/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | Mereo BipPharma Group | MREO | Downgrade | Neutral (Overweight) |
0.36 (0.31) |
-13.89% | Details | |
| 12/17/2025 | Recursion Pharmaceuticals | RXRX | Upgrade | Overweight (Neutral) |
4.20 (2.95) |
-29.76% | Details | |
| 8/25/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2025 | Mereo BipPharma Group | MREO | New Coverage | Overweight (N/A) |
2.35 (0.36) |
-84.68% | Details |
